PIPELINE
Therapeutics in development with the potential to treat deadly cancers.
Lumigen is advancing a pipeline of antibody-guided nanocomplex therapeutics built on its proprietary NOVVA™ platform. Each NOVVA™ is designed to target a specific cancer receptor and deliver a high, localized drug payload directly into tumor cells. This modular architecture enables rapid adaptation across multiple tumor types and payloads while maintaining a common development framework.
| Program | Target Indication | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
LUM-001 Fn14-targeted NOVVA™ |
Fn14-positive Triple Negative Breast Cancer |
-
Therapeutic Area: Fn14+ Triple Negative Breast Cancer
Program Overview: Our first-in-class lead program, LUM-001, demonstrates NOVVA’s potential in multiple Fn14-expressing solid tumors. Fn14 is a cell surface receptor minimally expressed in most normal adult tissues but highly upregulated in triple-negative breast cancer (TNBC), glioblastoma, ovarian, pancreatic, and other aggressive solid tumors, with no approved targeted therapy. LUM-001 is currently being advanced for the treatment of TNBC, one of the most aggressive and difficult-to-treat forms of breast cancer.
LUM-001 utilizes Fn14 to precisely target cancer cancer cells with paclitaxel, a widely used chemotherapy. By selectively targeting Fn14-positive tumors, LUM-001 is designed to improve intratumoral drug delivery while minimizing exposure to healthy tissues.
In multiple preclinical models of TNBC, LUM-001 has demonstrated superior efficacy compared with the current standard of care, supporting its continued advancement toward IND-enabling development. Success in TNBC is expected to establish the foundation for expanding LUM-001 into additional Fn14-positive cancers.